RCS - Biotech Growth Trust - Edison issues review on The Biotech Growth Trust

Biotech Growth TrustAnnouncement

16/03/2023 10:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230316:nRSP2279Ta&default-theme=true

RNS Number : 2279T  Biotech Growth Trust PLC (The)  16 March 2023

London, UK, 16 March 2023

 

Edison issues review on The Biotech Growth Trust (BIOG)

The Biotech Growth Trust (BIOG) has been managed by global healthcare
specialist OrbiMed Capital since May 2005. During its tenure, the trust has
outperformed its benchmark, the NASDAQ Biotechnology Index. OrbiMed favours
the prospects for emerging (smaller-cap) biotech stocks rather than large-cap
biotech businesses, as this is where the most industry innovation occurs.
BIOG's manager, Geoff Hsu, considers innovation to be the most important
driver of the biotech sector's long-term positive performance. He believes
that we remain in a 'golden era', evidenced by an expanding pipeline of new
drug candidates across all therapeutic areas. The manager expects an
acceleration in mergers and acquisitions (M&A) as major pharma companies,
facing patent expirations, seek to bolster their product pipelines by
acquiring smaller biotech companies.

 

BIOG's 9.2% share price discount to cum-income NAV is wider than the 3.9% to
6.8% range of average discounts over the last one, three, five and 10 years.
There is potential for a narrower discount; the trust considerably
outperformed its benchmark between Q120 and Q121, and during this time BIOG's
discount narrowed, and its shares regularly traded close to NAV.

Click here
(https://www.edisongroup.com/research/keeping-the-faith-in-smaller-cap-biotech-stocks/32089/?utm_campaign=RNS%20Press%20Releases&utm_source=RNS&utm_medium=Press%20Release)
to view the full report or here
(https://share.hsforms.com/1xWgTZ4FTQ7KIe9TkD-Gq6A3k1vq) to sign up to receive
research as it is published.

 

All reports published by Edison are available to download free of charge from
its website

www.edisongroup.com (http://www.edisongroup.com)

About Edison: Edison is a leading research and investor relations consultancy,
connecting listed companies to the widest pool of global investors. By
focusing on the volume and quality of investors reached - across institutions,
family offices, wealth managers and retail investors - Edison can create and
gauge intent to purchase, even in the darkest pools of capital, and then make
introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100
analysts covering every economic sector. Headquartered in London, Edison also
has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in
Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority
(https://register.fca.org.uk/ShPo_FirmDetailsPage?id=001b000000MfYL6AAN) .

Edison is not an adviser or broker-dealer and does not provide investment
advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Mel Jenner +44 (0)20 3077 5700 investmenttrusts@edisongroup.com
(mailto:investmenttrusts@edisongroup.com)

Learn more at www.edisongroup.com (http://www.edisongroup.com) and connect
with Edison on:

LinkedIn        www.linkedin.com/company/edison-group-/
(http://www.linkedin.com/company/edison-group-/)

Twitter             www.twitter.com/Edison_Inv_Res
(http://www.twitter.com/Edison_Inv_Res)

YouTube       www.youtube.com/edisonitv
(http://www.youtube.com/edisonitv)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGPUUCWUPWGUQ